Author

Bar Nathansohn

Weizmann Institute of Science

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Neuroscience· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

Angham Ibraheem· 2 shared Hannah Partney· 2 shared Michal SchwartziD· 2 shared Miguel Angel AbellanasiD· 2 shared Yuliya Androsova· 2 shared Aleksandra DeczkowskaiD· 1 shared Alexander KertseriD· 1 shared Ana García‐OstaiD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersNeuroscience

Angham Ibraheem

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Systemic administration of PD-L1 blocking antibodies leads to removal of senescent microglia

Yuliya Androsova, Alexander Kertser, Hannah Partney, Bar Nathansohn, Angham Ibraheem, Miguel Angel Abellanas, Tommaso Croese, Tomer Meir Salame, Hagay Akiva, Valery Krizhanovsky, Michal Schwartz

The paper shows that systemic PD-L1 blockade removes senescent microglia in mice, reducing neuroinflammation and suggesting a therapeutic role in Alzheimer's disease.

bioRxiv · Dec 24, 2025 · PreprintNeuroscience

Alzheimer's disease causes bone marrow myelopoiesis dysfunction

Miguel Angel Abellanas, Leyre Basurco, Maitreyee Purnapatre, Chiara Burgaletto, Giulia Castellani, Sarah Phoebeluc Colaiuta, Javier María Peralta Ramos, Angham Ibraheem, Sama Murad, Paola Antonello, Mariangeles Kovacs, Yuliya Androsova, Bar Nathansohn, Hannah Partney, Liora Cahalon, , Michal Schwartz

This study identifies impaired bone marrow myelopoiesis in Alzheimer's disease, driven by type I interferon signaling, and shows that targeting this pathway improves myeloid function and cognitive outcomes.

bioRxiv · Oct 6, 2025 · PreprintNeuroscience